Ongoing Trials
- A study of olezarsen administered subcutaneously in patients with severe hypertriglyceridaemia (sHTG) (NCT05681351)
- A study of olezarsen administered to participants with severe hypertriglyceridaemia (sHTG) (NCT05079919)
- A study of olezarsen (AKCEA-APOCIII-LRx) in participants with familial chylomicronaemia syndrome (NCT05130450)
- A study of olezarsen in participants with severe hypertriglyceridaemia (sHTG) and atherosclerotic cardiovascular disease (ASCVD) or with sHTG (NCT05610280)
- A study of olezarsen (AKCEA-APOCIII-LRx) in adults with familial chylomicronaemia syndrome (FCS) previously treated with volanesorsen (NCT05185843)
- A study of olezarsen in adults with hypertriglyceridaemia and atherosclerotic cardiovascular disease (ASCVD) and/or with severe hypertriglyceridaemia (sHTG) (Bridge-TIMI73a, NCT05355402)
- A study of olezarsen administered subcutaneously to participants with severe hypertriglyceridaemia (sHTG) (NCT05552326)
Completed Trials
- Phase 2 study of AKCEA-APOCIII-LRx in patients with hypertriglyceridaemia and established cardiovascular disease (CVD) (NCT03385239)
- Phase 1/2a safety, tolerability, PK and PD study of AKCEA-APOCIII-LRx in healthy volunteers with elevated triglycerides (NCT0290027)
- The Balance study of olezarsen (formerly AKCEA-APOCIII-LRx) administered to patients with familial chylomicronaemia syndrome (NCT04568434)
